China Nod At Regulatory Improvements Will Widen Doors For US Medtech
This article was originally published in Clinica
Executive Summary
Chinese officials have agreed to address regulatory challenges to improve access for US firms to China's medical device market following talks with American counterparts and medical device industry representatives. The targeted reforms include lowering clinical trial barriers for some class II and class III devices.
You may also be interested in...
China's Medtech Regulatory Reforms Yet To Enter Steady Path
Medical device companies operating in China are still looking for clearer guidance that will help them make the most of the wide-ranging regulatory reforms introduced in the country since 2014.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.